Microtubule detyrosination alters nuclear mechanotransduction and leads to pro-hypertrophic signaling in hypertrophic cardiomyopathy

This study demonstrates that in hypertrophic cardiomyopathy, microtubule detyrosination drives nuclear morphological abnormalities and impaired mechanotransduction, leading to pathological YAP1 signaling and hypertrophy, which can be reversed by inhibiting detyrosination.

The Gist

The Big Picture: A Heart That's Too Stiff and a Nucleus That's Too Busy

Imagine your heart is a busy factory. Inside every worker (heart cell), there is a Control Room (the nucleus) that holds the blueprints (DNA) and decides what the factory should build. To keep the factory running smoothly, the Control Room needs to be flexible and able to react to the rhythm of the work.

In a condition called Hypertrophic Cardiomyopathy (HCM), the heart muscle gets thick and stiff, and it struggles to relax between beats. Scientists have known for a while that the "scaffolding" inside these cells (called the cytoskeleton) gets messed up. But this new study discovered something surprising: the problem isn't just the scaffolding; it's how that scaffolding is crushing the Control Room.

The Problem: The "Rigid Cage" Effect

Think of the heart cell's scaffolding as a network of micro-tubes (microtubules). In a healthy heart, these tubes are flexible and stretchy, like rubber bands. They connect the outside of the cell to the Control Room (the nucleus) via a special bridge called the LINC complex.

In HCM patients, these micro-tubes get a chemical "glue" added to them called detyrosination.

• The Analogy: Imagine replacing your rubber bands with steel pipes.
• The Result: These steel pipes are too stiff. When the heart muscle tries to squeeze (contract), the steel pipes don't bend. Instead, they push and shove against the Control Room.

What Happens to the Control Room?

Because the steel pipes are pushing so hard, the Control Room gets distorted:

1. It gets squished and wrinkled: Instead of being a smooth oval, the nucleus becomes bumpy and deeply folded (like a crumpled piece of paper).
2. It gets stuck: When the heart muscle squeezes, the nucleus should squish a little bit to feel the rhythm. But because the steel pipes are so stiff, the nucleus can't move. It's like trying to dance while wearing a cast on your leg.
3. The Alarm System goes off: The nucleus has a security guard named YAP1. Normally, YAP1 stays outside the Control Room. But because the nucleus is being squeezed and wrinkled by the steel pipes, the "doors" (nuclear pores) get wobbly. YAP1 slips inside.

Once YAP1 is inside the Control Room, it starts shouting, "BUILD MORE MUSCLE!" This causes the heart to get even thicker and stiffer, creating a vicious cycle.

The Experiment: Fixing the "Steel Pipes"

The researchers wanted to see if they could fix this by removing the "glue" from the micro-tubes. They used a special drug called epoY.

• The Analogy: Think of epoY as a rust remover or a lubricant that turns the steel pipes back into flexible rubber bands.
• The Result:
  • When they treated the heart cells with epoY, the stiff pipes became flexible again.
  • The Control Room stopped getting squished and wrinkled; it returned to its smooth shape.
  • The nucleus could finally move with the heartbeat again.
  • Most importantly, YAP1 stopped slipping inside. The "Build More Muscle" alarm turned off.

Why This Matters

This study is a big deal for two reasons:

1. It explains the "Why": It shows that the heart isn't just getting thick because of bad genes; it's getting thick because the cell's internal structure is physically crushing the control center, triggering a panic response.
2. It offers a new cure: Instead of just trying to manage symptoms, doctors might one day use drugs like epoY to "lubricate" the cell's scaffolding. This would stop the nucleus from getting crushed, stop the false alarms, and potentially stop the heart from getting dangerously thick in the first place.

The Takeaway

In simple terms: HCM is like a factory where the support beams have turned into steel pipes, crushing the manager's office. This makes the manager panic and order more construction, making the factory even bigger and worse. The solution? Turn those steel pipes back into flexible rubber bands to let the manager breathe and stop the panic.

Technical Summary

1. Problem Statement

Hypertrophic Cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, diastolic dysfunction, and arrhythmia risk. While sarcomere mutations (e.g., in MYBPC3) are known causes, the downstream mechanisms linking cytoskeletal remodeling to nuclear dysfunction remain poorly understood.

• Context: Previous work established that HCM involves extensive cytoskeletal remodeling, specifically increased levels of tubulin, desmin, and detyrosinated $\alpha$-tubulin. Detyrosinated microtubules create a viscoelastic load that impairs cardiac relaxation.
• Gap: Microtubules connect to the nucleus via the LINC complex (Linker of Nucleoskeleton and Cytoskeleton), transmitting mechanical forces. However, it is unknown whether the altered microtubule landscape in HCM disrupts nuclear morphology, mechanics, and mechanosensitive signaling pathways (specifically YAP1), thereby driving pathological hypertrophy.

2. Methodology

The study utilized a multi-modal approach combining human patient tissue, a genetically engineered mouse model, and pharmacological interventions.

• Human Samples:
  • HCM Patients ($N=19$): Septal myectomy tissue (10 Genotype-positive, 9 Genotype-negative).
  • Controls ($N=8$): Non-failing donor (NF) left ventricular tissue.
  • Techniques: Transmission Electron Microscopy (TEM) for ultra-structural nuclear analysis; Immunofluorescence (IF) for 2D/3D nuclear morphology; Western Blotting for protein quantification (tubulin isoforms, Lamin A/C, YAP1); RT-qPCR for gene expression.
• Mouse Model:
  • Strain: Mybpc3^{c.2373InsG/InsG} (homozygous) mice, which recapitulate human HCM (hypertrophy, diastolic dysfunction, increased detyrosinated tubulin).
  • Controls: Wild-Type (WT) and heterozygous littermates.
  • Live-Cell Imaging: Isolated cardiomyocytes were paced at 1 Hz while stained with SPY505-DNA to visualize nuclear deformation in real-time.
• Pharmacological Interventions:
  • EpoY: A specific inhibitor of microtubule detyrosination (reduces detyrosinated tubulin without destabilizing the entire network).
  • Nocodazole: A general microtubule destabilizer.
  • Application: Used to test causality by rescuing nuclear phenotypes in Mybpc3^InsG/InsG cardiomyocytes.
• Analysis: Automated image analysis pipelines (NIS-elements, Fiji) quantified nuclear volume, invagination length, circularity, chromatin condensation, and YAP1 nuclear/cytoplasmic ratios.

3. Key Contributions

1. Discovery of Nuclear Phenotype in HCM: First comprehensive characterization showing that HCM nuclei are not only hypertrophic (enlarged) but also highly invaginated and mechanically stiffened (restricted deformability) during contraction.
2. Mechanistic Link: Established a causal link between microtubule detyrosination and nuclear mechanotransduction failure. The study demonstrates that detyrosinated microtubules act as a "mechanical buffer," preventing the nucleus from deforming in sync with sarcomere shortening.
3. Signaling Pathway Identification: Identified YAP1 (Yes-associated protein 1) as a key downstream effector. The study shows that nuclear invaginations and altered mechanics drive YAP1 nuclear translocation independent of canonical Hippo pathway phosphorylation, leading to pro-hypertrophic gene expression.
4. Therapeutic Proof-of-Concept: Demonstrated that pharmacologically reducing microtubule detyrosination (via EpoY) rescues nuclear morphology, restores nuclear deformability, and reduces YAP1 signaling, suggesting a novel therapeutic target.

4. Key Results

A. Nuclear Morphology and Mechanics

• Human & Mouse Data: Both HCM patients and Mybpc3^InsG/InsG mice exhibited significantly larger nuclei with increased invaginations compared to controls.
• Correlation: The degree of nuclear invagination correlated with the thickness of the interventricular septum (IVS) in patients and with nuclear area in mice.
• Deformability Defect: Live-cell imaging revealed that while sarcomere shortening kinetics were similar in WT and HCM cells, HCM nuclei failed to deform proportionally.
  • In WT, nuclear length decreased linearly with sarcomere shortening.
  • In HCM, nuclear deformation plateaued after ~1/3 of sarcomere shortening, indicating a "mechanical uncoupling" or buffering effect.
  • HCM nuclei showed increased hysteresis (energy loss) during the contraction-relaxation cycle.

B. Molecular Mechanism: Microtubules and YAP1

• Protein Levels: HCM tissue showed elevated total $\alpha$-tubulin, detyrosinated $\alpha$-tubulin, and acetylated $\alpha$-tubulin. Lamin A/C levels were unchanged, ruling out nuclear stiffness due to lamins.
• YAP1 Translocation: HCM samples showed increased nuclear localization of YAP1 and upregulation of YAP1 target genes (CYR61, ANKRD1) and hypertrophic markers (MYH7, NPPA, NPPB).
• Hippo Independence: Western blots showed no change in YAP1 phosphorylation (p-S127), indicating that YAP1 nuclear entry was driven by mechanical forces (nuclear tension/curvature) rather than canonical Hippo signaling.
• Correlation: A strong positive correlation was found between nuclear invagination length and nuclear YAP1 levels.

C. Pharmacological Rescue

• EpoY Treatment (Detyrosination Inhibitor):
  • Reduced nuclear invagination length.
  • Restored nuclear deformability (nuclei shortened in sync with sarcomeres).
  • Reduced nuclear YAP1 accumulation and normalized YAP1 target gene expression.
• Nocodazole Treatment (Microtubule Destabilizer):
  • Restored nuclear deformability but did not reduce nuclear invaginations or YAP1 nuclear levels.
  • Interpretation: This suggests that while general microtubule disruption restores mechanics, the specific detyrosination state is the critical driver of the pathological nuclear architecture and YAP1 signaling.

5. Significance and Clinical Implications

• Pathophysiological Insight: The study redefines the role of the cytoskeleton in HCM, moving beyond contractile dysfunction to include nuclear mechanotransduction. It proposes that stiff, detyrosinated microtubules tethered to the sarcomere prevent the nucleus from compressing, creating localized high-curvature sites (invaginations) that facilitate the import of mechanosensitive transcription factors like YAP1.
• Therapeutic Target: Targeting microtubule detyrosination (rather than just microtubule density) emerges as a promising strategy. It addresses both the diastolic dysfunction (by reducing viscoelastic load) and the maladaptive gene expression (by normalizing nuclear mechanics and YAP1 signaling).
• Broad Applicability: The findings apply to both Genotype-positive and Genotype-negative HCM patients, suggesting that cytoskeletal-nuclear coupling is a convergent pathological pathway regardless of the initial genetic trigger.
• Future Directions: The authors propose that long-term modulation of detyrosinated tubulin could reverse hypertrophy and improve diastolic function, offering a new class of therapies for heart failure.